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Background—Evidence from Europe, Asia, and North America suggests that standard three-
drug regimens of a proton pump inhibitor plus amoxicillin and clarithromycin are significantly 
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less effective for eradicating Helicobacter pylori (H. pylori) infection than five-day concomitant 
and ten-day sequential four-drug regimens that include a nitroimidazole. These four-drug 
regimens also entail fewer antibiotic doses and thus may be suitable for eradication programs in 
low-resource settings. Studies are limited from Latin America, however, where the burden of H. 
pylori-associated diseases is high.
Methods—We randomised 1463 men and women ages 21–65 selected from general populations 
in Chile, Colombia, Costa Rica, Honduras, Nicaragua, and Mexico (two sites) who tested positive 
for H. pylori by a urea breath test (UBT) to: 14 days of lansoprazole, amoxicillin, and 
clarithromycin (standard therapy); five days of lansoprazole, amoxicillin, clarithromycin, and 
metronidazole (concomitant therapy); or five days of lansoprazole and amoxicillin followed by 
five of lansoprazole, clarithromycin, and metronidazole (sequential therapy). Eradication was 
assessed by UBT six–eight weeks after randomisation.
Findings—In intention-to-treat analyses, the probability of eradication with standard therapy was 
82·2%, which was 8·6% higher (95% adjusted CI: 2·6%, 14·5%) than with concomitant therapy 
(73·6%) and 5·6% higher (95% adjusted CI: −0·04%, 11·6%) than with sequential therapy 
(76·5%). In analyses limited to the 1314 participants who adhered to their assigned therapy, the 
probabilities of eradication were 87·1%, 78·7%, and 81·1% with standard, concomitant, and 
sequential therapies, respectively. Neither four-drug regimen was significantly better than standard 
triple therapy in any of the seven sites.
Interpretation—Standard 14-day triple-drug therapy is preferable to five-day concomitant or 
ten-day sequential four-drug regimens as empiric therapy for H. pylori among diverse Latin 
American populations.
Funding—Bill & Melinda Gates Foundation and US National Institutes of Health.
Introduction
Helicobacter pylori (H. pylori) infects most of the world’s adult population and is the 
principal cause of gastric cancer, accounting for an estimated 60 per cent of all cases.1–3 
Gastric cancer is second only to lung cancer as a cause of cancer death worldwide, and the 
vast majority of the nearly one million cases and three-quarters of a million deaths each year 
occur in East Asia and Latin America.4 Although gastric cancer death rates have fallen in 
recent decades, the number of deaths has actually increased as a consequence of aging 
populations, and gastric cancer is projected to rank among the ten leading global causes of 
death by the year 2030.5–6 H. pylori is also the major cause of peptic ulcer disease, a 
condition responsible for an estimated 4·6 million disability adjusted life years lost annually 
worldwide, with most of the burden borne by populations in low- and middle-income 
countries.7 Population-wide eradication programs appear to offer the most direct approach to 
reducing the enormous human and economic consequences of H. pylori infection; however, 
none has been implemented to date.8
Large programs of H. pylori eradication require a practical and inexpensive antibiotic 
regimen that is effective in the specific locale where it will be used. Standard antibiotic 
regimens for H. pylori usually entail a proton pump inhibitor, amoxicillin, and 
clarithromycin, taken together over 7–14 days.9–11 However, the effectiveness of these 
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triple-therapy regimens appears to have diminished over time, largely as a result of 
emerging resistance of the organism to clarithromycin.12–13 Recent meta-analyses have 
shown that regimens that add a nitroimidazole (metronidazole or tinidazole) to triple therapy 
and are given either sequentially for ten days or concomitantly for five days are significantly 
more successful at eradicating H. pylori than are triple-therapy regimens.14–16 They also 
require fewer doses of antibiotics and thus may be more affordable in low-resource settings. 
Almost all of the evidence supporting these four-drug regimens comes from Europe and 
Asia; there are scant data from Latin America, a region with some of the world’s highest 
gastric cancer mortality rates.17 We therefore undertook a randomised trial in Latin America 
comparing the effectiveness of four-drug regimens given concomitantly or sequentially to 
that of a standard 14-day regimen of triple therapy. The trial also provided insights into the 
feasibility of community-based programs of H. pylori eradication.
Methods
Study population, recruitment, and eligibility
The trial (SWOG S0701) was conducted at seven centres in: Chile (Santiago), Colombia 
(Túquerres), Costa Rica (Guanacaste), Honduras (Santa Rosa de Copán), Mexico (Ciudad 
Obregón; and Tapachula), and Nicaragua (León). The institutional review boards for each 
clinical centre and for the SWOG Statistical Center in Seattle approved the study protocol. 
The trial was registered with clinicaltrials.gov; registration number NCT01061437.
Between September 2009 and June 2010, study research staff recruited potential participants 
from the general population of adult men and women aged 21–65 years and explained the 
purpose and eligibility requirements of the study to them. The sites in Colombia, Costa Rica, 
and Nicaragua selected individuals from a census of households. The Chilean site used a list 
of individuals served by a large public primary care clinic. Staff in Honduras and the two 
sites in Mexico recruited participants by walking house-to-house within the local community 
or through announcements at primary care clinics. Study participants in Tapachula 
(Mexico), Nicaragua, and Chile were predominantly urban, and those in the other sites were 
from small, rural communities. Potential participants were deemed ineligible if they had 
been treated in the past for H. pylori, had serious illnesses that might end their lives before 
completing the study, or had other conditions that required or precluded therapy with 
antibiotics or proton pump inhibitors. They also had to agree to abstain from alcohol use for 
at least two weeks. Those who expressed an interest in participating and signed their 
informed consent then completed an interview regarding socio-economic characteristics and 
health history and a detailed gastrointestinal symptom history assessment using the validated 
Spanish language version of the Rome III Diagnostic Questionnaire for the Adult Functional 
Gastrointestinal Disorders (www.theromefoundation.org/).18,19
Urea breath test procedures
Participants provided a urea breath test (UBT) for H. pylori infection by exhaling into foil 
balloons before, and 30 minutes after, consuming a 75 mg dose of 13C-labelled urea with 
water. Staff at each centre analysed the breath samples using an infrared mass spectrometry 
device (IRIS, Wagner Analysen Technik GmbH, Bremen, Germany) that produced a 
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computer-generated result of positive (delta over baseline ≥4·0%) or negative (delta over 
baseline <2·5%); intermediate values were classified as inconclusive. If a participant 
reported using an antibiotic or proton pump inhibitor within the past 15 days, or if the UBT 
result was inconclusive, the test was rescheduled for a later date.
Randomisation, interventions and blinding
Participants who had a positive UBT and met all other eligibility criteria were assigned at 
random, in equal proportions, to one of three treatment groups: a) standard triple therapy of 
lansoprazole 30 mg, amoxicillin 1,000 mg, and clarithromycin 500 mg taken twice a day for 
14 days; b) concomitant therapy of lansoprazole 30 mg, amoxicillin 1,000 mg, 
clarithromycin 500 mg, and metronidazole 500 mg taken twice a day for five days; and c) 
sequential therapy of lansoprazole 30 mg and amoxicillin 1,000 mg taken twice a day for 
five days followed by lansoprazole 30 mg, clarithromycin 500 mg, and metronidazole 500 
mg taken twice a day for five days. Each clinical centre purchased its own supply of the 
drugs, as generic (off-patent) preparations, from suppliers in country, except that the centres 
in Honduras and Nicaragua both used the same supplier in Honduras. The drug suppliers 
provided quality-control data regarding the content and dissolution of each medication. 
Randomisation was implemented through a web-based dynamic balancing procedure at the 
SWOG Statistical Center to assure balance of sex and age (21–40 versus 41–65) within 
centre across the three regimens. All participants were randomised within two weeks 
following their positive UBT result. The trial was not blinded.
Follow-up
Study staff contacted participants at least once during treatment to encourage adherence and 
to remind them to return any unused doses at their follow-up visit, which was scheduled to 
occur six-to-eight weeks after randomisation. During follow-up visits, participants 
completed another interview concerning adherence to therapy, their reasons for missing any 
doses of the regimens, and the occurrence of any new or worsened medical conditions that 
led them to seek medical attention. Study staff counted the number of medication doses 
returned and administered the follow-up UBT.
Statistical considerations
We designed the study to address two primary hypotheses. The first was that five-day 
concomitant therapy is not inferior to 14-day standard therapy, where inferior is defined as a 
difference in eradication probability of 5% or greater in favour of standard therapy. We 
reasoned that the shorter duration and lower cost associated with concomitant therapy would 
make it preferable to standard therapy if it were not appreciably less effective in eradicating 
H. pylori. Our second hypothesis was that ten-day sequential therapy would be more 
effective than 14-day standard therapy, because a four-drug sequential regimen would be 
preferred over standard three-drug therapy only if it were clearly superior in eradicating H. 
pylori. Assuming an eradication rate of 80% for standard therapy,10% missing follow-up 
UBT results, and 210 randomised participants per centre (1470 total), each treatment arm 
contrast would have 82% power to detect a difference of 8% or greater, based on a two-
sided 0·025-level test. Although the meta-analysis indicated that concomitant therapy was 
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about 10% better than sequential therapy,16 if the therapies were actually equivalent the trial 
would have 46% power to reject the inferiority of concomitant therapy, based on a one-
sided, 0·025 level test.
Our primary statistical analyses adhered to the intention-to-treat principal and included all 
randomised eligible participants, with those lacking a definitive follow-up UBT considered 
to be treatment failures (UBT positive). Comparison of concomitant to standard therapy 
employed a two-sample z-test of the null hypothesis that the difference in the estimated 
probabilities of eradication was 5% or greater in favour of the standard regimen, based on a 
one-sided test of non-inferiority. Comparison of sequential to standard therapies was based 
on a two-sample z-test for no difference between eradication probabilities. Sensitivity to 
missing data assumptions was examined by excluding data from the participants without a 
conclusive follow-up UBT. To explore how lack of adherence may have affected our 
conclusions, we further restricted the analyses to participants with a definitive UBT who had 
taken at least 80% of their assigned study medications.
Secondary analyses explored variability in treatment outcomes by sex, age, presence of 
chronic dyspeptic symptoms, and clinical centre. Tests of interaction were calculated as 
deviance tests comparing logistic regression models with the treatment arm indicators, the 
designated covariate, and their interaction terms, to those without the interaction terms.
All analyses were done using SAS and R statistical software. To account for the two primary 
comparisons, Bonferroni-adjusted 95% confidence intervals are presented and p-values less 
than 0·025 are considered statistically significant. No corrections for multiplicity were 
applied to secondary analyses, as they are considered exploratory. All p-values are two-
sided except the test of non-inferiority.
Role of the funding sources
The Bill & Melinda Gates Foundation provided financial support for the trial, and the 
National Institutes of Health (Grant # CA037429) supported SWOG administrative and 
statistical infrastructure. The funding entities were not involved in the design, conduct of the 
trial, the analysis and interpretation of study data, or the preparation and submission of the 
manuscript. All authors participated in the decision to submit the manuscript and had 
complete access to the data.
Results
A total of 1859 potentially-eligible adults agreed to participate and completed the screening 
interview and intake questionnaire, but seven withdrew before the UBT. The UBT was 
positive for 79% (1471 of 1852) of the tested participants. Eight patients with a positive 
UBT were not randomised because they opted not to be treated, could not be randomised 
within two weeks of their UBT, or had a disqualifying condition (e.g., pregnancy). Six 
participants with a negative UBT who were randomised incorrectly because of data entry 
errors were withdrawn from the study before receiving treatment, and their data are not 
included in any of the following analyses. Of the eligible participants who were randomised, 
59% (861 of 1463) were women, 58% (847 of 1463) were older than 40 years, and 26% 
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(373 of 1462) had chronic dyspeptic symptoms as classified by the Rome III criteria. 
Participant characteristics did not differ substantially among the three treatment arms (Table 
1). Forty-seven participants did not return for their follow-up UBT, and two participants had 
follow-up UBTs that were inconclusive after two repeat tests. Thus, we obtained a definitive 
follow-up UBT result for 97% (1414 of 1463) of the randomised eligible participants 
(Figure 1).
Over 92% (1315 of 1416) of participants who returned for their follow-up visit had taken at 
least 80% of their assigned medications, as assessed by pill count and self-report (Table 2). 
In all, 102 participants reported that they missed taking at least some of their medicines 
because of concerns about side effects; 41, 28, and 33 patients in the standard, concomitant, 
and sequential arms, respectively. Five participants experienced new, therapy-related 
symptoms (stomach discomfort, nausea/vomiting, or fatigue/weakness) that led them to seek 
medical attention, one in the standard treatment arm and two each in the concomitant and 
sequential treatment arms.
In intention-to-treat analyses, the estimated 82·2% (401 of 408) probability of eradicating H. 
pylori with 14-day standard triple therapy was 8·6% higher (95% adjusted CI: 2·6%, 14·5%) 
than with five-day concomitant therapy and 5·6% (95% adjusted CI: −0·04%, 11·6%) higher 
than with ten-day sequential therapy (Table 3). The null hypothesis of inferiority of 
concomitant therapy to standard therapy could not be rejected (one-sided p=0·91); thus, the 
data are consistent with five-day concomitant therapy being inferior to 14-day standard 
therapy. The difference between ten-day sequential therapy and standard therapy was not 
statistically significant (p=0·037) at the p=0·025 level, but the near statistical significance of 
this two-sided test suggests that sequential therapy was not as effective as standard therapy. 
Sensitivity analyses that excluded participants without a definitive follow-up UBT and those 
confined to participants who had adhered to the prescribed regimens showed similar patterns 
of treatment contrasts as the intention-to-treat analysis, but with somewhat higher estimated 
eradication probabilities (Table 3). Secondary analyses examining potential interactions 
revealed no statistically significant interactions between treatment and sex (p=0·91), age 
(p=0·21), presence of chronic dyspeptic symptoms at baseline (p = 0·38), or study centre 
(p=0·28). There were differences among centres in the overall probability of eradication in 
both the intention-to-treat population (Table 4) and the adherent-to-therapy population 
(Table 5, supplementary material), but nowhere was either four-drug regimen clearly 
superior to standard triple therapy.
Discussion
This multi-centre randomised trial of three regimens for eradicating H. pylori involved a 
large sample of adults recruited from the general populations of seven Latin American sites. 
The prevalence of H. pylori infection among screened participants was high, and nearly all 
individuals who tested UBT-positive were randomised into the trial. Participants tended to 
adhere closely to the protocol by returning for their follow-up UBT and taking their 
prescribed tablets. There was little difference among the three treatment arms in adherence 
and serious side effects. Our principal outcome measure, the probability of H. pylori 
eradication, was higher for 14-day standard triple therapy than for both four-drug regimens, 
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and these results did not vary significantly by age, sex, study site, or history of chronic 
dyspeptic symptoms.
H. pylori presents a major global health challenge that probably can best be addressed 
through practical, inexpensive, and population-based interventions in the resource-limited 
countries where it is most prevalent. From this perspective our trial’s size, technical 
simplicity, broad geographic coverage within Latin America, community-based population, 
use of locally-sourced generic drugs, and statistically robust findings across important 
subgroups reflect the realities of a region where H. pylori-associated diseases are especially 
burdensome. The trial results are important in that they contradict those of meta-analyses 
that indicated that four-drug regimens (triple therapy plus a nitroimidazole) given 
concomitantly or sequentially were clearly superior to triple therapy,14–16 and they suggest 
that findings based primarily on data from Europe and other high-income regions may not 
be readily generalizable to lower-income countries.
We observed probabilities of H. pylori eradication of less than 80% with five-day 
concomitant and ten-day sequential regimens by the intention-to-treat analysis, whereas 
meta-analyses had reported probabilities greater than 90% for both.14–16 A more recent trial 
from Taiwan comparing-day regimens of concomitant versus sequential four-drug therapies 
also reported that both regimens were more than 90% successful.20 The estimated 
effectiveness of our three-drug regimen (82%) in the intention-to-treat analysis was only 
modestly greater than found in the meta-analyses (77%–79%). Thus, the divergence between 
our findings and those of the meta-analyses largely represents the substantially worse 
performance of the four-drug regimens.
Geographic variations in the pattern of H. pylori resistance to antibiotics might account for 
some of these discrepancies in results. In clinical series from several of the countries where 
our trial was conducted, clarithromycin resistance in H. pylori isolates has been reported to 
be less prevalent than in Europe, and metronidazole resistance substantially more prevalent 
(as high as 80%).21–24 Clarithromycin resistance strongly diminishes the effectiveness of 
triple therapy, so a better outcome with triple therapy would be expected if the prevalence of 
resistance in our trial population actually was low. 13,21,25 A high prevalence of resistance to 
metronidazole in our study population is a plausible, but less certain, explanation for the 
worse-than-expected success of the four-drug regimens.25 Results according to antibiotic 
resistance are available from only two trials of sequential therapy versus triple therapy, and 
the combined data showed that sequential therapy was successful in 96% (68 of 71) of 
patients with metronidazole-resistant organisms compared to 78% (46 of 59) for triple 
therapy.16,26 There are no comparable data from trials of concomitant versus triple therapy. 
The presence of organisms resistant to both antibiotics would likely cause treatment to fail 
for all three studied regimens, but there are only scant data on this topic from Latin America.
We employed a 14-day regimen of triple therapy, whereas prior trials of the four-drug 
regimens generally compared them to seven or ten days of triple therapy. In one meta-
analysis 14-day triple therapy regimens were slightly, but statistically significantly, superior 
to those of seven days or ten days; thus, longer duration conceivably enhanced the 
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performance of triple therapy in our trial.27 Success with the four-drug regimens perhaps 
would also improve with greater duration;13,20,28 however, this would increase their cost.
We drew our participants from the general population of adults in the community, whilst 
prior trials studied patients with gastrointestinal symptoms.14–16 The success of H. pylori 
treatment with triple therapy or sequential therapy has not been shown to be affected by a 
diagnosis of peptic ulcer disease or dyspepsia, and the superiority of triple therapy over the 
four-drug regimens in our trial did not vary significantly according to history of chronic 
dyspeptic symptoms.14 Although our trial was not blinded, the outcome measure (UBT) was 
objectively determined and seems unlikely to be biased. We used locally-available generic 
sources of drugs, but the differences in treatment response among centres cannot be easily 
attributed to variable drug quality, since some of the greatest differences were seen between 
Nicaragua and Honduras, centres that obtained their drugs from the same source.
For individuals with H. pylori infection in much of Latin America, 14 days of triple therapy 
is probably the preferred empiric treatment. Nevertheless, the 87% eradication success in 
participants who adhered to the regimen is suboptimal in the clinical setting, and its 
effectiveness may decrease over time as clarithromycin resistance increases. Better H. pylori 
treatment regimens for Latin American populations conceivably could be designed based on 
local antibiotic resistance data. However, the relatively small number of published reports 
on antibiotic resistance in this region generally pertain to H. pylori isolates obtained from 
symptomatic patients undergoing endoscopy in urban, academic centres, and thus their 
results might not be applicable to broader populations.21 Lacking representative data on 
resistance, and given the daunting technical and financial challenges of obtaining these data, 
treatment guidelines for Latin America and other regions with limited resources may have to 
rely primarily on the results of large, simple clinical trials of empiric therapies in the specific 
populations to which the guidelines would apply. These data could be supplemented by 
subsequent monitoring of effectiveness in practice over time and by the results of antibiotic 
resistance testing in selected patients, where feasible.
We designed our study as a preliminary step towards implementing programs of gastric 
cancer prevention in Latin America. H. pylori-associated gastric cancer results from a 
decades-long progression from normal mucosa to invasive cancer.3,29 The most promising 
preventive approach appears to be eradication of H. pylori before cancer develops, and a 
number of randomised clinical trials have evaluated this strategy. The results show that 
eradicating H. pylori slows or reverses progression of pre-malignant histological lesions, but 
no trial has been large enough to show a definitive cancer-preventive effect.30,31 
Nevertheless, analyses have indicated that H. pylori eradication programs would be cost-
effective over the long term if they prevented only 10% of gastric cancer deaths; over the 
short term they would reduce costs of care for peptic ulcers and dyspepsia symptoms.32–34 
Eradication programs are potentially even more cost-effective in regions such as Latin 
America, where the burden of H. pylori-associated diseases is greater.
Our trial experience suggests that population-wide clinical trials or public health programs 
of H. pylori eradication are feasible in Latin America. UBT-positive individuals readily 
agreed to be randomised to antibiotic treatment, and all three regimens of generic drugs 
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resulted in probabilities of eradication comparable to those obtained in prior prevention 
programs.31 The 14-day triple-drug regimen had superior results, but the lower cost of the 
shorter-duration regimens may make them acceptable for use in preventive programs where 
resources are particularly scarce. Other considerations, including risks of recrudescence and 
re-infection following eradication, will also be important considerations.
Panel: Research in context
Systematic review—Consensus groups that represent both global and Latin American 
perspectives have designated triple-drug regimens of a proton pump inhibitor plus 
amoxicillin and clarithromycin taken for 7–14 days as a standard approach for eradicating 
H. pylori.10,11 However, the effectiveness of these regimens appears to have diminished to 
unacceptably low levels over time, and recent meta-analyses of clinical trials from Europe 
and Asia indicate that four-drug regimens that add metronidazole or tinidazole to triple 
therapy achieve superior results.12–16 A Medline search revealed no reports of relevant trials 
from Latin America, an area where H. pylori-associated diseases are common and where 
wide-scale eradication programs may be indicated.
Interpretation—Our findings show that in the Latin American populations we studied, in 
contrast to many European and some Asian populations, 14-day standard triple therapy is 
more effective than five-day concomitant or ten-day sequential four-drug regimens that 
include metronidazole for eradicating H. pylori. One thus cannot safely assume that the 
observed effectiveness of H. pylori eradication regimens in one area will apply equally well 
elsewhere.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Participant Characteristics by Treatment Arm
14-day Standard 5-day Concomitant 10-day Sequential Total
N=488 N=489 N=486 N=1463
Center (N, %)
 Santiago, Chile 69 (14·1) 70 (14·3) 70 (14·4) 209 (14·3)
 Túquerres, Colombia 71 (14·5) 72 (14·7) 69 (14·2) 212 (14·5)
 Guanacaste, Costa Rica 70 (14·3) 70 (14·3) 70 (14·4) 210 (14·4)
 Copán, Honduras 70 (14·3) 72 (14·7) 71 (14·6) 213 (14·6)
 Tapachula, México 71 (14·5) 69 (14·1) 70 (14·4) 210 (14·4)
 Obregón, México 70 (14·3) 69 (14·1) 71 (14·6) 210 (14·4)
 León, Nicaragua 67 (13·7) 67 (13·7) 65 (13·4) 199 (13·6)
Sex (N, %)
 Female 287 (58·8) 288 (58·9) 286 (58·8) 861 (58·9)
 Male 201 (41·2) 201 (41·1) 200 (41·2) 602 (41·1)
Age (N, %)
 20–29 66 (13·5) 66 (13·5) 91 (18·7) 223 (15·2)
 30–39 137 (28·1) 139 (28·4) 117 (24·1) 393 (26·9)
 40–49 142 (29·1) 117 (23·9) 127 (26·1) 386 (26·4)
 50+ 143 (29·3) 167 (34·2) 151 (31·1) 461 (31·5)
Education (N, %)
 4 or fewer years 88 (18·0) 77 (15·7) 80 (16·5) 245 (16·7)
 5–8 years 135 (27·7) 166 (33·9) 143 (29·4) 444 (30·3)
 9–12 years 146 (29·9) 135 (27·6) 136 (28·0) 417 (28·5)
 13 or more years 71 (14·5) 71 (14·5) 70 (14·4) 212 (14·5)
 Not Reported 48 (9·8) 40 (8·2) 57 (11·7) 145 (9·9)
Chronic Dyspeptic Symptoms (N, %)
 Present 125 (25·6) 121 (24·7) 127 (26·1) 373 (25·5)
 Absent 363 (74·4) 368 (75·3) 359 (73·9) 1090 (74·5)
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Table 2
Adherence by treatment arm among patients that returned for 6-week follow-up
Returned for 6-week follow-up
Standard Concomitant Sequential Total
N=475 N=471 N=470 N=1416
Amount of Medication Taken (N, %)*
 All (100%) 427 (89·9) 442 (93·8) 437 (93) 1306 (92·2)
 Nearly all (>80%) 7 (1·5) 0 (0) 2 (0·4) 9 (0·6)
 Most (50%–80%) 24 (5·1) 14 (3) 21 (4·5) 59 (4·2)
 Less than half (<50%) 10 (2·1) 8 (1·7) 5 (1·1) 23 (1·6)
 Undetermined (but not all) 7 (1·5) 5 (1·1) 5 (1·1) 17 (1·2)
 None 0 (0) 2 (0·4) 0 (0) 2 (0·1)
Reasons for not taking all meds (N, %)**
 Concern about having or developing side effects 41 (8·6) 28 (5·9) 33 (7·0) 102 (7·2)
 Unrelated illness/injury 3 (0·6) 1 (0·2) 5 (1·1) 9 (0·6)
 Forgot or inconvenient 36 (7·6) 25 (5·3) 37 (7·9) 98 (6·9)
 Reason not given 0 (0) 3 (0·6) 2 (0·4) 5 (0·4)
*
Based on count of returned medication and self-report among participants who returned for a follow-up UBT.
**
Multiple responses allowed.
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